These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3078574)

  • 1. Effect of the thromboxane receptor antagonist, BM 13.505, on the sequelae of endotoxemia in the conscious rat.
    Smith EF; Jugus M; Kinter LB
    Eicosanoids; 1988; 1(1):27-33. PubMed ID: 3078574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of the thromboxane receptor antagonists BM 13.177 and BM 13.505 against U 46619-induced sudden death in rats.
    Smith EF; McDonald J
    Pharmacology; 1988; 36(5):340-7. PubMed ID: 3406046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate against 9,11-dideoxy- 9 alpha, 11 alpha-epoxymethano-prostaglandin F2 alpha-induced sudden death in guinea-pigs and rats.
    Shirakura S; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1242-5. PubMed ID: 1815523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
    Smith EF; Griswold DE; Egan JW; Hillegass LM; DiMartino MJ
    J Cardiovasc Pharmacol; 1989 May; 13(5):715-22. PubMed ID: 2472519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the thrombolytic agent, streptokinase, on the responses to endotoxemia in conscious rats.
    Smith EF; Kinter LB; Jugus M; Zeid R
    Circ Shock; 1988 Jun; 25(2):85-94. PubMed ID: 3292078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death.
    Lefer DJ; Mentley RK; Lefer AM
    Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentration-dependent, stereoselective inhibition of the endotoxin-induced hemoconcentration in conscious rats with the peptidoleukotriene receptor antagonist SK & F 104353.
    Smith EF; Kinter LB; Jugus M; Eckardt RD; Newton JF
    Eicosanoids; 1989; 2(2):101-7. PubMed ID: 2560662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of the peptidoleukotriene receptor antagonist, SK&F 104353, on the responses to experimental endotoxemia in the conscious rat.
    Smith EF; Kinter LB; Jugus M; Wasserman MA; Eckardt RD; Newton JF
    Circ Shock; 1988 May; 25(1):21-31. PubMed ID: 3042186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
    Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
    Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of BAY U 3405, a thromboxane A2 receptor antagonist, in endotoxin shock.
    Altavilla D; Canale P; Squadrito F; Sardella A; Ammendolia L; Urna G; Ioculano M; Squadrito G; Caputi AP
    Pharmacol Res; 1994; 30(2):137-51. PubMed ID: 7816742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a selective V1 vasopressin receptor antagonist on the sequelae of endotoxemia in the conscious rat.
    Egan JW; Jugus M; Kinter LB; Lee K; Smith EF
    Circ Shock; 1989 Oct; 29(2):155-66. PubMed ID: 2684446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
    Griswold DE; Egan JW; Earl CQ; Hillegass LM; Marshall PJ; Smith EF
    Prog Clin Biol Res; 1989; 301():161-5. PubMed ID: 2529547
    [No Abstract]   [Full Text] [Related]  

  • 14. BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion.
    Smith EF; Earl CQ; Egan JW
    Prostaglandins Leukot Essent Fatty Acids; 1989 Oct; 38(1):15-23. PubMed ID: 2532749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets.
    Patscheke H; Stegmeier K
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():371-3. PubMed ID: 3159225
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of thromboxane receptor antagonists on venous thrombosis in rats.
    Schumacher WA; Heran CL
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1109-15. PubMed ID: 2522985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the LTD4 receptor antagonist LY203647 on endotoxic shock sequelae in the rat.
    Li EJ; Cook JA; Ashton S; Wise WC; Halushka PV
    Eur J Pharmacol; 1991 Jun; 199(2):221-5. PubMed ID: 1954979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SK&F 86002 inhibits tumor necrosis factor formation and improves survival in endotoxemic rats.
    Smith EF; Slivjak MJ; Bartus JO; Esser KM
    J Cardiovasc Pharmacol; 1991 Nov; 18(5):721-8. PubMed ID: 1723769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of SK&F 96148 on thromboxane-mediated responses in the airways of the cat.
    Dyson MC; Kadowitz PJ
    Eur J Pharmacol; 1991 May; 197(1):17-25. PubMed ID: 1909957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations.
    Karasawa A; Shirakura S; Higo K; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1237-41. PubMed ID: 1815522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.